Picture of Nautilus Biotechnology logo

NAUT Nautilus Biotechnology Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Nautilus Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-9.62-15.6-50.3-57.9-63.7
Depreciation
Non-Cash Items-0.1132.310.111.713.3
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.479-1.39-0.022-0.788-3.22
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-9.66-14-39.2-45.8-51.7
Capital Expenditures-0.926-0.921-2.27-2.32-2.44
Purchase of Fixed Assets
Other Investing Cash Flow Items4.98-24.4-137-23.4-41.3
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities4.05-25.3-139-25.7-43.7
Financing Cash Flow Items75.93270
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities0.03675.93270.5620.368
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-5.5836.6149-71-95.1